Oral vs Injectable Peptides: Which Works?

The Core Difference

Peptides are short chains of amino acids. Your digestive system exists to break amino acid chains apart. That single fact explains why most peptides are injected rather than swallowed.

When you inject a peptide subcutaneously, the intact molecule enters the tissue beneath your skin and absorbs into the bloodstream. Nothing degrades it. Nothing breaks it apart. The full dose reaches circulation in its active form.

When you swallow a peptide capsule, it passes through stomach acid (pH 1.5-3.5) and encounters digestive enzymes (pepsin, trypsin, chymotrypsin) whose entire job is to cleave peptide bonds. Most of the active compound is degraded before it ever reaches the intestinal wall where absorption happens. What survives still has to cross the intestinal epithelium and pass through the liver (first-pass metabolism) before reaching systemic circulation.

Bioavailability: The Numbers

Subcutaneous injection delivers close to 100% bioavailability. The peptide enters the body intact and is absorbed directly into blood and lymphatic circulation.

Oral peptide bioavailability is harder to pin down because it varies by peptide, formulation, and whether the capsule includes protective coatings. Conservative estimates for unprotected oral peptides range from 1 to 15%. Some enteric-coated or specially formulated oral peptides may achieve higher absorption, but published data on oral peptide bioavailability in humans is limited.

Drucker DJ, "Advances in oral peptide therapeutics," Nature Reviews Drug Discovery, 2020. View study

The practical implication: if you take 500mcg of BPC-157 orally, somewhere between 50 and 75mcg may reach systemic circulation as intact peptide. The same 500mcg injected subcutaneously delivers the full dose. For conditions that require systemic delivery, this difference matters.

When Oral Peptides Make Sense

Oral delivery has one major advantage that injection cannot match: direct contact with the GI tract. For conditions affecting the stomach, intestinal lining, or gut barrier function, an oral peptide works at the site of the problem before it gets degraded.

BPC-157 is the strongest case for oral delivery. It is derived from a protein in human gastric juice. When taken orally, it contacts the stomach and intestinal lining directly, which is exactly where it evolved to work. For patients dealing with leaky gut, IBS, gastric inflammation, or food sensitivities, oral BPC-157 puts the compound where it is needed most.

Oral delivery also makes sense for patients who cannot or will not self-inject. Some people have genuine needle phobias. Others travel frequently and prefer the convenience of capsules. A lower-bioavailability oral dose that the patient actually takes consistently is better than a high-bioavailability injection that sits in the refrigerator unused.

When Injectable Is Better

For anything requiring systemic delivery, such as tendon repair, ligament healing, muscle recovery, body composition, growth hormone optimization, immune modulation, sleep, and cognitive function, injectable is the standard of care. The bioavailability gap is too large for oral delivery to compete in these applications.

Growth hormone peptides (CJC-1295/Ipamorelin, Sermorelin, Tesamorelin) must be injected. They would be destroyed in the gut. Metabolic peptides (MOTS-c, AOD-9604), neurological peptides (DSIP, Selank), immune peptides (Thymosin Alpha-1), and longevity peptides (Epitalon, NAD+, GHK-Cu) are all injectable for the same reason.

For BPC-157 specifically targeting a musculoskeletal injury (torn tendon, damaged ligament, joint inflammation), injection is preferred because you can deliver the full dose subcutaneously near the injury site. The peptide reaches the damaged tissue at therapeutic concentration rather than being diluted through the entire GI tract.

BPC-157: The Oral Exception

BPC-157 occupies a unique position because it works both systemically (when injected) and locally in the gut (when taken orally). This is not true of most peptides.

The reason is its origin. BPC-157 is a fragment of a protein your stomach already produces. The gastric environment is its natural habitat. While digestive enzymes break down most peptides, BPC-157 shows unusual stability in acidic conditions, likely because it evolved to function in that environment.

Sikiric P et al., "Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157: vascular recruitment and gastrointestinal tract healing," Current Pharmaceutical Design, 2018. Preclinical (rodent) gastric work. View study

PeRx offers both BPC Capsules (oral BPC-157) and injectable BPC-157. The choice depends on what you are treating. Gut issues point toward oral. Musculoskeletal injuries point toward injection. Some patients use both simultaneously, oral for gut healing and injectable for a knee or shoulder, though this should be discussed with your provider.

Side-by-Side Comparison

Frequently Asked Questions

Reviewed by Dr. Cory Mellon, MD · Last reviewed April 2026